STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
STAAR Surgical Price Performance
STAA opened at $87.72 on Tuesday. The firm has a fifty day moving average price of $73.35 and a 200 day moving average price of $70.00. STAAR Surgical has a 1 year low of $49.03 and a 1 year high of $163.08. The stock has a market cap of $4.19 billion, a P/E ratio of 151.24 and a beta of 1.09.
Analysts Set New Price Targets
STAA has been the topic of a number of research reports. Canaccord Genuity Group raised their target price on shares of STAAR Surgical from $81.00 to $89.00 and gave the company a "buy" rating in a research report on Tuesday, April 26th. Canaccord Genuity Group lifted their price objective on shares of STAAR Surgical from $81.00 to $89.00 and gave the stock a "buy" rating in a research report on Tuesday, April 26th. BTIG Research reaffirmed a "buy" rating and issued a $98.00 price objective on shares of STAAR Surgical in a research report on Saturday, April 23rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $87.00 price objective on shares of STAAR Surgical in a research report on Tuesday, May 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $92.00.
Insider Buying and Selling
In other news, CEO Caren L. Mason sold 35,000 shares of the company's stock in a transaction on Thursday, May 19th. The shares were sold at an average price of $57.49, for a total transaction of $2,012,150.00. Following the completion of the sale, the chief executive officer now owns 83,645 shares of the company's stock, valued at $4,808,751.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.60% of the stock is owned by insiders.